First patient dosed in Phase III clinical trial for PET radiopharmaceutical Next stage clinical study also proceeding for SPECT radiopharmaceutical Both imaging agents aim to assist in the evaluation ...
Thanks to a new diagnostic imaging technique, physicians now have an objective test to evaluate patients for parkinsonian syndromes, such as Parkinson's disease. Northwestern Memorial Hospital is ...
January 17, 2011 — GE Healthcare has announced Food and Drug Administration (FDA) approval of ioflupane iodine-123 injection (DaTscan), a contrast agent for use with single-photon emission computed ...
DaTscan is a radioactive diagnostic agent that works by binding reversibly to the human dopamine transporter (DaT) in the brain. The Food and Drug Administration (FDA) has expanded the approval of ...
Guelph Medical Imaging (GMI) says a new exam now available at its clinic on Dawson Road is able to definitively tell patients if they have Parkinsonian Syndromes, such as Parkinson’s Disease. DaTscan ...
Parkinson’s disease (PD), the second-most common neurodegenerative disease, is characterized by motor and nonmotor symptoms. PD is often misdiagnosed; inappropriate treatment due to misdiagnosis has ...
The DaTscan, a special type of dopamine transporter imaging brain scan, may help doctors predict how a newly diagnosed patient’s Parkinson’s disease will progress, researchers from the University of ...
The FDA has approved DaTscan (Ioflupane I 123 Injection, from GE Healthcare) for use with single photon emission computed tomography (SPECT) imaging, for the detection of dopamine transporters (DaT) ...
SCOTTSDALE, Ariz., April 24, 2023 /PRNewswire/ -- SimonMed is proud to announce we will offer GE HealthCare's radiopharmaceutical diagnostic tracer, DaTscan™ (Ioflupane I 123 injection), with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback